Haplotypes of the Adrenergic System Predict the Blood Pressure Response to β-Blockers in Women with Essential Hypertension

Filigheddu, Fabiana; Argiolas, Giuseppe; Degortes, Simona; Zaninello, Roberta; Frau, Francesca; Pitzoi, Silvia; Bulla, Emanuela; Bulla, Patrizia; Troffa, Chiara; Glorioso, Nicola

doi:10.2217/pgs.09.158

Cited by 37 publications

(19 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, negative studies, including larger, well-powered investigations, predominate suggesting that rs1801253 cannot reliably predict antihypertensive response, rate control, or heart failure outcomes 11,17,[53][54][55][56][57][58] .…”

Section: Candidate Pharmacodynamic Polymorphisms Of Adrenergic Responsementioning

confidence: 99%

See 1 more Smart Citation

A Physiologic Approach to the Pharmacogenomics of Hypertension

Eadon

Chapman

2016

Advances in Chronic Kidney Disease

View full text Add to dashboard Cite

Section: Candidate Pharmacodynamic Polymorphisms Of Adrenergic Responsementioning

confidence: 99%

“…A single trial suggested the C allele of variant rs5443 is associated with improved SBP response to atenolol 54 . This trial suggested that two additional SNPs, rs11064426 and rs2301339, were also associated with atenolol response.…”

Section: Candidate Pharmacodynamic Polymorphisms Of Adrenergic Responsementioning

confidence: 99%

A Physiologic Approach to the Pharmacogenomics of Hypertension

Eadon

Chapman

2016

Advances in Chronic Kidney Disease

View full text Add to dashboard Cite

“…However, no significant genotype based effects of ADRB1 Ser49 and Arg389 polymorphism have been observed with dobutamine (Aquilante et al, 2008) or fluoxetine and paoxetine in Caucasian Americans (Turner et al, 2008). ADRB1 Ser49Gly and Arg389Gly and ADRB2 Cys19Arg, Gly16Arg and Gln27Glu polymorphisms were also not found to significantly affect BP response to Atenolol (Filigheddu et al, 2010). In contrast, Pacanowski et al (2008) found Ser49Gly and Arg389Gly to be significantly associated with response to atenolol in a study of 5,979 patients from 184 sites in the United States and Puerto Rico.…”

Section: β-Blockersmentioning

confidence: 94%

“…Three SNPs in the GNB3 gene, A3882C, G5249A and C825T have been found to have a significant effect on blood pressure response to atenolol in the female participants in Caucasian Americans (Filigheddu et al, 2010). Carvedilol is a non-selective and blocker that reduces the BP by blocking the binding of Norepinephrine to 1-and 2-adrenergic receptors (Stafylas & Sarafidis, 2008).…”

Section: β-Blockersmentioning

confidence: 99%

Pharmacogenetics of Essential Hypertension

Khullar¹,

Sharma²

2012

Genetics and Pathophysiology of Essential Hypertension

View full text Add to dashboard Cite

“…These studies investigated the association of RAS gene polymorphisms and responses to antihypertensive drugs, including angiotensin I-converting enzyme inhibitors (ACEIs), 13 angiotensin II receptor blockers (ARBs), 14 beta blockers 15 and diuretics. 16 Our group also endeavored to clarify the susceptible gene polymorphisms to thiazide diuretics 17 and calcium channel blockers (CCBs) 18 by candidate genes approaches, although there are very limited reports about gene polymorphisms associated with the effects of CCBs.…”

Section: Current Trends In Pharmacogenetic/ Pharmacogenomic Studies Omentioning

confidence: 99%

Pharmacogenomic approaches to study the effects of antihypertensive drugs

2012

View full text Add to dashboard Cite

Pharmacogenomic studies aim to clarify the role of various genes and their variations in relation to the effects of antihypertensive drugs to establish a personalized pharmacotherapeutic treatment based on a patient's genetic background. Until recently, there have been numerous pharmacogenetic/pharmacogenomic studies on antihypertensive drugs using candidate genes, but only a few genome-wide approaches have been completed. In this review article, we discuss current trends and future directions of pharmacogenomic studies on antihypertensive drugs. Hypertension Research (2012) 35, 796-799; doi:10.1038/hr.2012; published online 28 June 2012 Keywords: antihypertensive drugs; candidate genes; GWAS; pharmacogenomics; tailored medicine INTRODUCTION Hypertension is the most common risk factor for atherosclerotic cardiovascular diseases, and its morbidity is greater than 50% in subjects aged 65 years and older in Japan and most Western countries. In Japan, the number of patients with hypertension is estimated to be greater than 40 million. 1 Hypertension is a multifactorial disease in which genetic and environmental factors are closely related. Specifically, genetic factors can influence blood pressure elevation by 30-50%. 2 Thus, over the last decade, many genetic studies have aimed to clarify the causal genes of hypertension, as reviewed previously. 3 Genetic research on hypertension started using the candidate gene approach by investigating renin-angiotensin system (RAS)-related genes. [4][5][6] Recently, several large-scale genome-wide association studies (GWASs) for hypertension 7-9 were performed, and B50 single nucleotide polymorphisms (SNPs) were identified as possible causal genes.The goal of genetic studies on hypertension is mainly to clarify the causal genes of hypertension and the mechanisms of blood pressure elevation. Consequently, these approaches may lead to the production of novel antihypertensive drugs. Another important aim is to establish personalized pharmacotherapy based on genetic information. These were the two main aims of the Japanese Millennium Project for Hypertension. 10 As mentioned, the first aim may be reasonably addressed by large-scale GWAS, but the second aim has not yet been examined in the field of hypertension research.Recent studies indicate that the heterogeneity of patients' responses to antihypertensive treatment is, at least in part, genetically determined. 11 This finding underscores the role of pharmacogenetic/ pharmacogenomic research in identifying either functional genetic variations or those variations inherited by linkage disequili-

show abstract

Haplotypes of the Adrenergic System Predict the Blood Pressure Response to β-Blockers in Women with Essential Hypertension

Abstract: Our study confirmed the sex-specific association of GNB3 with the blood pressure response to atenolol with no substantial advantage of the analysis of haplotypes over SNPs.

Cited by 37 publications

References 45 publications

A Physiologic Approach to the Pharmacogenomics of Hypertension

A Physiologic Approach to the Pharmacogenomics of Hypertension

Pharmacogenetics of Essential Hypertension

Pharmacogenomic approaches to study the effects of antihypertensive drugs

Contact Info

Product

Resources

About